In the present study, we aimed to examine, using mouse AAA models, whether EP4 antagonist‐mediated AAA attenuation is a class effect, and investigate whether an EP4 antagonist inhibits matrix metalloproteinase (MMP) activation and cytokine release in human smooth muscle cells isolated from patients with AAA (hAASMCs). This evidence concerns the gene PTGER4 and triple-A syndrome.